The SIRveNIB Study
SIRveNIB is a multi-centre prospective randomised open-label study to compare the efficacy and safety of SIR-Spheres® Y-90 resin microspheres versus sorafenib. The study recruited >360 patients in Asia who were ineligible for potentially curative therapies, such as surgical resection, ablation or liver transplantation.
The primary endpoint of the SIRveNIB study is Overall Survival. Secondary endpoints include Safety, Progression-Free Survival (PFS) in the liver, PFS at any site, Tumour Response Rate, Liver Resection Rate, Liver Transplantation Rate, Quality of Life, and Healthcare Costs.
The study completed enrolment in May 2016 and results are expected by mid-2017.